Andrew is the Director of Operations of Antibody Analytics and co-founder of the company. He has overall responsibility for the implementation of the company's R&D strategy alongside delivery of client projects.
Andrew started his scientific career with Covance Laboratories in the bioanalytical department providing testing services to the biopharmaceutical industry in 2006. After completing an MRes. in Medical and Molecular Biosciences and PhD in Neuroscience at Newcastle University in 2011, Andrew spent time in the clinical projects group at Roche co-ordinating clinical trials to protect market share of large molecule biologics such as Herceptin from biosimilar competition. With experience gained in in vitro assays, in vivo research and clinical trials, Andrew was invited to work for BioOutsource in Glasgow and was employed as the first Assay Development Scientist in the newly formed Biosimilar R&D Department, ultimately becoming a Senior Scientist. During this time, he was responsible for the development, optimisation and validation of broad range of assay formats used to characterise biosimilar monoclonal antibodies encompassing functional assays as well as a wide variety of binding technologies including ELISA, MSD and SPR methods for use in the characterisation of a range of biological drugs. He established a dedicated team of scientists that performed functional and binding assays for clients worldwide to support their drug development programmes in BioOutsource's Biosimilar Centre of Excellence.